The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication

Gene Therapy

Volumn 5, Issue 12, 1998, Pages 1705-1711

  Touraine, R L ^a,b   Ishii Morita, H ^a   Ramsey, W J ^a   Blaese, R M ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Bystander effect; Ganciclovir; Gap junction; Gene therapy; Herpes simplex virus thymidine kinase

Indexed keywords

ANTIVIRUS AGENT; DIELDRIN; DYE; FORSKOLIN; GANCICLOVIR; THYMIDINE KINASE;

ANIMAL CELL; ARTICLE; CANCER; CELL COMMUNICATION; CELL KILLING; CONTROLLED STUDY; GAP JUNCTION; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR CELL LINE;

ANIMALIA; HERPES; SIMPLEXVIRUS;

EID: 0032440742     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300784     Document Type: Article

References (13)

1. Mullen CA. Metabolic suicide genes in gene therapy. Pharmacol Ther 1994; 63: 199-207.
2. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990; 82: 297-300.
3. Cheng Y et al. Metabolism of 9-(1,3-dihydroxy-2-propoxymethyl) guanine, a new anti-herpes virus compound, in herpes simplex virus-infected cells. J Biol Chem 1983; 258: 12460-12464.
4. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-5281.
5. Culver KW et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors (see comments). Science 1992; 256: 1550-1552.
6. Freeman SM et al. The bystander effect: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
7. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum Gene Ther 1993; 4: 725-731.
8. Pitts JD. Cancer gene therapy: a bystander effect using the gap junctional pathway. Mol Carcinogen 1994; 11: 127-130.
9. Fick J et al. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci USA 1995; 92: 11071-11075.
10. Mesnil M et al. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 1996; 93: 1831-1835.
11. Elshami A et al. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Therapy 1996; 3: 85-92.
12. Vrionis F et al. The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions. Gene Therapy 1997; 4: 577-585.
13. Mesnil M, Yamasaki H, Piccoli C. A tumor suppressor gene, Cx26, also mediates the bystander effect in HeLa cells. Cancer Res 1997; 57: 2929-2932.